Eli Lilly (LLY) rose to $1,482.59, up 4.64%, after its October 29 third-quarter update showed revenue up 39% to $24.4 billion and raised full-year guidance. Price remains above the main moving aver...
Eli Lilly’s latest catalyst came from its October 29, 2026 third-quarter report, which showed revenue up 39% year over year to $24.4 billion, led mainly by Mounjaro and Zepbound. The company also raised the midpoint of 2026 full-year revenue guidance by $5.5 billion to a range of $91.0 billion to $92.0 billion and increased underlying non-GAAP EPS guidance at the midpoint by $4.07. Those results support the stock’s current pricing because they confirm that the company’s recent operating strength is still feeding through to forward guidance, not just prior-quarter results. citeturn0search0
Recent analyst updates are consistent with that backdrop, but they do not remove the short-term stretch in the shares. GuruFocus reported that Jefferies maintained a Buy rating on November 9, 2026 and raised its target to $1,700 from $1,610. Investing.com reported on November 2, 2026 that Cantor Fitzgerald raised its target to $1,600 from $1,440 while keeping an Overweight rating. stockanalysis.com says 31 analysts polled by S&P Global have a consensus Buy rating and an average price target of $1,460. The stock is already above that average, so the market is now leaning more on continued execution than on a fresh rerating. citeturn0search1turn0search2turn0search3
31 and 24-hour volume of $7,158,896 in the supplied Binance futures data. 50. The EMA stack is also supportive, with the 12-day EMA above the 26-day EMA.
Source link
